References
- Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629–55.
- O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. Rev Antimicrob Resist. 2016. London: HM Government. doi:10.1016/j.jpha.2015.11.005.
- WHO. Global action plan on antimicrobial resistance. http://apps.who.int/iris/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=.
- Vekemans J, Hasso-Agopsowicz M, Kang G, Hausdorff WP, Fiore A, Tayler E, Klemm EJ, Laxminarayan R, Srikantiah P, Friede M, et al. Leveraging vaccines to reduce antibiotic use and prevent antimicrobial resistance: a World Health Organization action framework. Clin Infect Dis. 2021;73(4):e1011–2. doi:10.1093/cid/ciab1062.
- Kennedy DA, Read AF. Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance. PNAS. 2018;115(51):12878–86. doi:10.1073/pnas.1717159115.
- WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25FebET_NM_WHO.pdf?ua=1.
- Vaccines Europe. The role of vaccination in reducing antimicrobial resistance (AMR). 2016 Nov. http://www.vaccineseurope.eu/wp-content/uploads/2016/11/VE-policy-paper-on-the-role-of-vaccines-in-reducing-AMR2016-FIN.pd.
- Bell E, Neri M, Steuten L. Towards a broader assessment of value in vaccines: the BRAVE way forward. Appl Health Econ Health Policy. 2022;20(1):105–11. doi:10.1007/s40258-021-00683-z.
- Leveraging vaccines to reduce antibiotic use and prevent antimicrobial resistance: an action framework: world health; 2020. Licence: CC BY-NC-SA 3.0 IGO.
- Kingwell K. RSV vaccines score landmark FDA approvals. Nat Rev Drug Discov News. 2023 May;31(7):523–5. doi:10.1038/d41573-023-00085-x.
- Arexvy. Recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E. EPAR. European Medicines Agency; 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/arexvy.
- WHO Regional Office for Europe/European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022 – 2020 data. Copenhagen: WHO Regional Office for Europe; 2022. https://www.ecdc.europa.eu/sites/default/files/documents/Joint-WHO-ECDC-AMR-report-2022.pdf.
- Piano Nazionale di Prevenzione Vaccinale 2023-2025. https://www.quotidianosanita.it/allegati/allegato1679488094.pdf.
- Piano Nazionale di Contrasto all’Antibiotico-resistenza (PNCAR) 2022-2025. Ministero della Salute. https://www.salute.gov.it/imgs/C_17_pubblicazioni_3294_allegato.pdf.
- AMR Task Force Project. Recommendations for an effective strategy on antimicrobial resistance. Pharmadvances. 2022 Nov Special Issue;4(No. 4–Special):7–15. http://www.pharmadvances.com/recommendations-for-an-effective-strategy-on-antimicrobial-resistance/.
- WHO. List of bacteria for which new antibiotics are urgently needed. 2017. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.
- A phase 1/2, observer-blind, randomized, placebo-controlled multi-country study to assess safety and efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) investigational vaccine when administered to healthy adults 18 to 50 years of age. NCT05630859. Clinicaltrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT05630859.